Infectious Disease Advisor news story
The M72/AS01 TB vaccine appears to be well tolerated among people with HIV (PWH) receiving antiretroviral therapy (ART), despite higher rates of short-term local and systemic reactions compared with placebo, according to study findings published in Open Forum Infectious Diseases.
PWH continue to experience an increased burden of TB despite treatment with ART. However, evidence regarding the safety of M72/AS01 in this population has been limited. Researchers conducted a systematic review and meta-analysis to characterize adverse events associated with M72/AS01 among PWH receiving ART.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #27, 12 October 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.